ACE Inhibitors In Veterinary Cardiology: Clinical Guide

Angiotensin-converting enzyme (ACE) inhibitors form a cornerstone of therapy for cardiovascular disorders in veterinary patients, particularly for managing chronic congestive heart failure (CHF) in dogs and cats. These medications work by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing vascular resistance, preload, and afterload while promoting natriuresis.

The Renin-Angiotensin-Aldosterone System in Animals

The renin-angiotensin-aldosterone system (RAAS) plays a critical role in maintaining blood pressure and fluid balance. In heart disease, RAAS activation leads to sodium and water retention, vasoconstriction, and cardiac remodeling, exacerbating CHF. ACE inhibitors interrupt this cascade at the enzyme level, mitigating these effects and improving cardiac output and exercise tolerance.

In dogs with conditions like dilated cardiomyopathy (DCM) or myxomatous mitral valve disease (MMVD), RAAS hyperactivity contributes to disease progression. Studies confirm that suppressing this system enhances hemodynamics and survival. Similarly, in cats, ACE inhibitors address hypertension-related organ damage.

Commonly Used ACE Inhibitors in Practice

Several ACE inhibitors are approved or commonly employed in veterinary medicine, primarily as prodrugs administered orally. Key options include:

• Benazepril: Widely used for CHF in dogs; converted to benazeprilat in the liver with good bioavailability that improves upon repeated dosing.
• Enalapril: Approved in the US for CHF due to DCM and MMVD; bioavailability around 60%, with active metabolite enalaprilat peaking in 3-4 hours.
• Imidapril and Ramipril: Approved in various regions for canine CHF, offering similar efficacy.

Captopril, once popular, is less favored due to gastrointestinal side effects and shorter half-life requiring frequent dosing. Selection often depends on availability, cost, and species-specific pharmacokinetics.

Pharmacokinetics Across Species

These profiles guide dosing intervals, often every 12 hours for sustained ACE suppression. In horses, benazepril outperforms enalapril due to better absorption and ACE inhibition.

Therapeutic Applications in Canine Patients

Dogs with CHF from valvular disease or cardiomyopathy benefit most from ACE inhibitors, which prolong survival and alleviate symptoms. Enalapril is FDA-approved for DCM and MMVD-related CHF. A retrospective study of 144 dogs found median dosing at 0.84 mg/kg/day, with twice-daily regimens optimizing outcomes without significant renal impacts.

ACE inhibitors also manage systemic hypertension, often combined with other vasodilators, and show antiproteinuric effects in renal disease. They are safe with diuretics and pimobendan.

Benefits for Feline Cardiovascular Health

Cats receive ACE inhibitors for CHF and hypertension, though evidence is less robust than in dogs. Benazepril and enalapril reduce cardiac filling pressures and improve tolerance. Monitoring is essential due to potential azotemia from altered renal autoregulation.

Equine Use and Considerations

In horses with mitral or aortic regurgitation, ACE inhibitors like benazepril enhance echocardiographic parameters and stroke volume. Quinapril also boosts cardiac output, but enalapril’s poor absorption limits its utility.

Dosing Strategies and Monitoring

Typical starting doses:

• Dogs: 0.5 mg/kg PO q12-24h (adjust per drug)
• Cats: 0.5 mg/kg PO q24-48h
• Horses: Benazepril 0.25-0.5 mg/kg PO q24h

Monitor BUN, creatinine, electrolytes, and blood pressure 1-2 weeks post-initiation, then periodically. Dose reductions occur in ~5% of cases due to adverse effects. Twice-daily dosing may maximize cardioprotection.

Safety Profile and Adverse Effects

ACE inhibitors boast excellent tolerability, combinable with most cardiovascular agents. Primary concern is azotemia from efferent arteriolar dilation impairing glomerular filtration, especially with diuretics. Hypotension is rare unless severe hypertension exists. Genetic ACE polymorphisms may influence baseline activity but not post-treatment response.

Comparative Insights: ACEIs vs. ARBs

While ARBs like telmisartan target angiotensin II receptors directly, ACE inhibitors prevent its formation. Both treat hypertension and proteinuria, but ACEIs remain first-line for CHF.

Evidence from Clinical Studies

Peer-reviewed data affirm ACE inhibitors’ efficacy: improved survival in canine CHF, dose-dependent benefits, and RAAS modulation. No evidence supports delaying subclinical disease onset.

Practical Guidelines for Veterinarians

1. Initiate in stable CHF patients.
2. Titrate based on response and labs.
3. Use q12h for optimal suppression.
4. Avoid monotherapy in severe hypertension.

Frequently Asked Questions (FAQs)

What are the main side effects of ACE inhibitors in pets?

Most common is mild azotemia; monitor renal values regularly.

Can ACE inhibitors be used with other heart medications?

Yes, safely with diuretics, pimobendan, and beta-blockers.

Are ACE inhibitors suitable for cats with hypertension?

Yes, particularly in combination therapies.

How do I dose benazepril in dogs?

Typically 0.25-0.5 mg/kg q12-24h, adjusting for response.

Do ACE inhibitors work in horses?

Benazepril is effective for valvular regurgitation.

Integrating ACE inhibitors into protocols transforms outcomes in veterinary cardiology, balancing efficacy with safety through vigilant monitoring.